Earnings ·
Alamar Biosciences raises full-year revenue guidance to $121M-$123M as Q3 revenue jumps 68% to $33.5 million
ALMRAlamar Biosciences, Inc.
Alamar Biosciences reported third-quarter 2026 total revenue of $33.5 million, a 68% increase from the prior-year period, driven by strong demand for consumables and services. The company raised its full-year 2026 revenue guidance to $121 million–$123 million, up from previous expectations of $116 million–$120 million. Additionally, President Tod White announced his retirement effective December 31, 2026, after which he will serve as a consultant through June 2027 to ensure an orderly transition. Alamar Biosciences operates in the biotechnology sector, specializing in precision proteomics and disease detection.